Long-term evolution of multiple sclerosis disability in the treatment era

Area of Science:

• Neurology
• Immunology
• Clinical Research

Background:

• Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Understanding long-term disability progression is crucial for effective patient management and treatment strategies.
• Current clinical trial data may not fully capture the long-term trajectory of MS.

Purpose of the Study:

• To characterize the long-term accrual of disability in actively treated multiple sclerosis (MS) patients.
• To evaluate the prognostic value of clinical and magnetic resonance imaging (MRI) data used in clinical trials for long-term outcomes.
• To assess the relationship between early disease activity, vitamin D levels, and long-term disability in MS.

Main Methods:

• Prospective study of 517 actively managed MS patients.
• Data collection up to 10 years post-baseline, with long-term follow-up.
• Assessment of neurological disability using the Expanded Disability Status Scale (EDSS) and MRI criteria for No Evidence of Disease Activity (NEDA).

Main Results:

• 41% of patients showed stable or improved EDSS scores at 10 years.
• No Evidence of Disease Activity (NEDA) in the first 2 years did not predict better long-term outcomes.
• 10.7% reached EDSS ≥ 6 and 18.1% evolved to secondary progressive MS (SPMS) at a median of 16.8 years post-onset.
• 25-OH vitamin D levels associated with short-term but not long-term MS activity.

Conclusions:

• Long-term disability accrual in actively treated MS patients appears slower than in historical natural history studies.
• The 2-year NEDA endpoint may not be a reliable predictor of long-term MS stability.
• The utility of annual MRI for a treat-to-target approach in MS care warrants further investigation.